INDIVIDUAL TEST 884
MOG Antibodies (IgG)
Indication
Suspicion of Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD) or MOG-associated disease (MOGAD)
Sample material
Serum
- Minim. volume: 0,5 mL
CSF
- Minim. volume: 0,5 mL
Transport
Within Sweden
- room temperature
International
- cold
Method
Cell-based assay (CBA), indirect immunofluorescence (IIF)
Reference interval
- Serum: <1:10 negative
- CSF: negative
Result
Results are reported as negative or positive. A positive result is followed by a titer (serum).
Interpretation
The presence of IgG-antibodies against MOG is associated with MOG associated disease (MOGAD). In MOGAD, antibodies against MOG can usually be detected in both serum and CSF, but in 10-20% of cases only in either serum or CSF.
If clinical suspicion of MOGAD remains after a negative result, complementary analysis with live Cell Based Assay (live CBA) is recommended in serum.
References
- Sato DK et al. Neurology. 2014. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. PMID: 24415568
- Reindl M et al. Neurol Neuroimmunol Neuroinflamm. 2020. International multicenter examination of MOG antibody assays. PMID: 32024795
- Majed M et al. Neurol Neuroimmunol Neuroinflamm. 2016. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. PMID: 27144221
- Höftberger R et al. Mult Scler. 2015. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. PMID: 25344373
- Wingerchuk DM et al. Neurology. 2015. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. PMID: 26092914
- Lycke J, Malmeström C. Lakartidningen. 2010. Neuromyelitis optica--viktig differentialdiagnos till MS. Tidigt insatt behandling avgörande för prognosen. PMID: 21294335
- Banwell B et al. Lancet Neurol. 2023. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. PMID: 36706773
- Paul F et al. Neurol Neuroimmunol Neuroinflamm. 2023. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. PMID: 37258412
- Petzold A et al. Lancet Neurol. 2022. Diagnosis and classification of optic neuritis. PMID: 36179757
Last updated: 2025-03-18
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 884
MOG-antikroppar (IgG)
Indikation
Misstanke om Multipel Skleros (MS), Neuromyelitis optica spectrum sjukdom (NMOSD) och MOG-associerad sjukdom (MOGAD)
Provmaterial
Serum
- Minim. volym: 0,5 mL
Likvor
- Minim. volym: 0,5 mL
Transport
Inom Sverige
- rumstemperatur
Internationellt
- kylt
Metod
Cell-based assay (CBA), indirekt immunofluorescens (IIF)
Referensintervall
- Serum: <1:10 negativt
- Likvor: negativt
Resultat
Resultat anges som negativt eller positivt. Positivt resultat titreras (serum).
Tolkning
Förekomst av IgG-antikroppar mot MOG är associerat med MOG associerad sjukdom (MOGAD). Vid MOGAD kan antikroppar mot MOG vanligen påvisas i både serum och likvor men i 10-20% av fallen endast i antingen serum eller likvor.
Vid negativt resultat och kvarstående klinisk misstanke om MOGAD rekommenderas kompletterande analys med live Cell Based assay (CBA) i serum.
Referenser
- Sato DK et al. Neurology. 2014. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. PMID: 24415568
- Reindl M et al. Neurol Neuroimmunol Neuroinflamm. 2020. International multicenter examination of MOG antibody assays. PMID: 32024795
- Majed M et al. Neurol Neuroimmunol Neuroinflamm. 2016. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. PMID: 27144221
- Höftberger R et al. Mult Scler. 2015. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. PMID: 25344373
- Wingerchuk DM et al. Neurology. 2015. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. PMID: 26092914
- Lycke J, Malmeström C. Lakartidningen. 2010. Neuromyelitis optica--viktig differentialdiagnos till MS. Tidigt insatt behandling avgörande för prognosen. PMID: 21294335
- Banwell B et al. Lancet Neurol. 2023. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. PMID: 36706773
- Paul F et al. Neurol Neuroimmunol Neuroinflamm. 2023. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. PMID: 37258412
- Petzold A et al. Lancet Neurol. 2022. Diagnosis and classification of optic neuritis. PMID: 36179757
Senast uppdaterat: 2025-03-18